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ABSTRACT
Here, we propose a new strategy for the treatment of early cancerous lesions and 
advanced metastatic disease, via the selective targeting of cancer stem cells (CSCs), 
a.k.a., tumor-initiating cells (TICs). We searched for a global phenotypic characteristic 
that was highly conserved among cancer stem cells, across multiple tumor types, 
to provide a mutation-independent approach to cancer therapy.  This would allow 
us to target cancer stem cells, effectively treating cancer as a single disease 
of “stemness”, independently of the tumor tissue type.  Using this approach, we 
identified a conserved phenotypic weak point – a strict dependence on mitochondrial 
biogenesis for the clonal expansion and survival of cancer stem cells. Interestingly, 
several classes of FDA-approved antibiotics inhibit mitochondrial biogenesis as a 
known “side-effect”, which could be harnessed instead as a “therapeutic effect”. 
Based on this analysis, we now show that 4-to-5 different classes of FDA-approved 
drugs can be used to eradicate cancer stem cells, in 12 different cancer cell lines, 
across 8 different tumor types (breast, DCIS, ovarian, prostate, lung, pancreatic, 
melanoma, and glioblastoma (brain)). These five classes of mitochondrially-targeted 
antibiotics include: the erythromycins, the tetracyclines, the glycylcyclines, an anti-
parasitic drug, and chloramphenicol.  Functional data are presented for one antibiotic 
in each drug class: azithromycin, doxycycline, tigecycline, pyrvinium pamoate, as 
well as chloramphenicol, as proof-of-concept.  Importantly, many of these drugs are 
non-toxic for normal cells, likely reducing the side effects of anti-cancer therapy. 
Thus, we now propose to treat cancer like an infectious disease, by repurposing FDA-
approved antibiotics for anti-cancer therapy, across multiple tumor types. These drug 
classes should also be considered for prevention studies, specifically focused on the 
prevention of tumor recurrence and distant metastasis. Finally, recent clinical trials 
with doxycycline and azithromycin (intended to target cancer-associated infections, 
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INTRODUCTION
Next generation sequencing and many other very 
sophisticated means of mutational analysis have given us 
an incredibly detailed view, or “molecular portrait”, of the 
diversity of genetic modifications that occur during the 
development of human cancers [1-5]. 
Despite this knowledge of the genomic landscape 
of cancer, it still remains extremely difficult to identify 
what are the primary “driver-mutations”, in the context of 
a “sea” of many other genetic changes [1-5]. The emerging 
picture is that while a few driver-mutations are common 
to certain specific cancer sub-types, each patient’s tumor 
is fairly unique in its complexity of genetic changes and 
that several divergent cancer cell clones may also co-exist, 
within a single tumor [1-5]. 
This enormous level of detail and genetic complexity 
makes it extremely difficult to design new diagnostics and 
targeted-therapeutics, to achieve the goals of personalized 
medicine. There are numerous examples in clinical 
practice of how targeting the suspected “driver mutations” 
has been disappointing. Cancer control is frequently short 
lived, even when these drugs are proven to be effective. 
For example, the BRAF inhibitor vemurafenib is approved 
for the treatment of patients whose melanoma harbors the 
V600E mutation, which is thought to be a driver mutation 
[6, 7]. However, after treatment with vemurafenib, cancer 
progression occurs within six months in the vast majority 
of these patients with V600E mutations [6, 7]. 
Instead, an alternative approach would be to focus 
on what is common between different tumor types, rather 
than on what is divergent between different cancers. 
One common tractable target may be the property of 
“stemness” in cancer cells. 
Recently, Tomasetti and Vogelstein showed that the 
life-time risk of two-thirds of cancers could simply be 
accounted for by the number of times that a given tissue’s 
stem cells undergo cell division [8]. This is consistent 
with the idea that during aging, somatic mutations may 
accumulate in tissue stem cells, driving the formation of 
cancer stem cells [8]. They further concluded that these 
somatic mutations accounted for more cancer cases than 
either inherited genetic disease or specific environmental 
risk factors. These observations are also consistent with 
the idea that cancer is essentially a disease of “stemness” 
gone awry [7, 8]. 
Based on this rather simple premise, using unbiased 
quantitative proteomic profiling [9], we have focused 
on identifying a global phenotypic property of cancer 
stem cells (CSCs) that could be targeted across multiple 
tumor types. We have identified this property as a 
strict dependence on mitochondrial biogenesis, for the 
anchorage-independent clonal expansion and survival of 
the CSC population. 
Here, we show that 4-to-5 different classes of 
FDA-approved antibiotics, which inhibit mitochondrial 
biogenesis as an “off-target” effect, can be used to 
eradicate cancer stem cells, in 12 different cancer cell 
lines, across 8 different tumor types (breast, DCIS, 
ovarian, prostate, lung, pancreatic, melanoma, and 
glioblastoma (brain)). Thus, future clinical trials for testing 
the efficacy of these mitochondrially-targeted antibiotics, 
in multiple cancer types, are now clearly clinically 
warranted. Overall, the use of generic antibiotics for 
anti-cancer therapy should significantly reduce the costs 
of patient care, making treatment more accessible in the 
developing world. 
RESULTS
Overall approach: Finding an Achilles’ heel in 
cancer stem cells
Recently, we used an unbiased proteomics approach 
to identify what makes cancer stem cells relatively unique, 
as compared with ‘bulk’ cancer cells [9]. For this purpose, 
we characterized the proteome of mammo-spheres derived 
from two different ER(+) breast cancer lines, specifically 
MCF7 and T47D cells [9]. Interestingly, we observed that 
MCF7 mammo-spheres show the marked over-expression 
of >60 mitochondrial-related proteins, as compared with 
monolayers; nine of these mitochondrial proteins were 
infinitely upregulated in mammo-spheres [9]. These 
findings are consistent with the idea that cancer stem cells 
are anabolic and that they may require mitochondrial 
biogenesis for their survival and proliferative expansion 
[9]. 
To test this hypothesis more directly, here we took 
advantage of the known side effects of specific classes of 
antibiotics. Because mitochondria evolved from bacteria 
that were originally engulfed by eukaryotic cells millions 
of years ago (known as the “endosymbiotic theory of 
mitochondrial evolution”) [10, 11], many classes of FDA-
approved antibiotics actually target mitochondria, as a 
mild side-effect, which is well-tolerated in most patients. 
More specifically, the erythromycins and 
chloramphenicol selectively bind to the large subunit of 
the mitochondrial ribosome and inhibit mitochondrial 
biogenesis, by preventing the translation of mitochondrial 
proteins, mainly related to the mitochondrial OXPHOS 
complexes (Figure 1A). Similarly, the tetracyclines 
and glycylcyclines both bind with high affinity to the 
small subunit of the mitochondrial ribosome and inhibit 
mitochondrial biogenesis as well (Figure 1A). 
but not cancer cells) have already shown positive therapeutic effects in cancer 
patients, although their ability to eradicate cancer stem cells was not yet appreciated. 
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Thus, these four large classes of antibiotics 
all function as known inhibitors of mitochondrial 
biogenesis in mammalian cells. This would allow us to 
use these antibiotics as “investigational tools” to assess 
if mitochondrial biogenesis is absolutely required for 
the survival and propagation of cancer stem cells. If 
successful, these FDA-approved antibiotics could then 
be re-purposed for the treatment of cancer, to achieve the 
eradication or more effective elimination of cancer stem 
cells (Figure 1B). 
If mitochondrial biogenesis is indeed required for 
the propagation of all cancer stem cells, then this new 
therapeutic approach could be applied across multiple 
cancer types, perhaps in a mutation independent fashion. 
In essence, we would be treating cancer based instead on 
a common global phenotypic property that is characteristic 
Figure 1: Treating cancer like an infectious disease, with antibiotics. Recently, using unbiased proteomics analysis, we showed 
that mitochondrial proteins were highly upregulated in MCF7 and T47D tumor-spheres, as directly compared with monolayer cells. 
Thus, we set out to test the hypothesis that tumor-sphere formation was strictly dependent on mitochondrial biogenesis. Interestingly, 
several known classes of FDA-approved antibiotics function as inhibitors of mitochondrial biogenesis, which results in manageable side-
effects. (A) Bacterial and mitochondrial ribosomes are closely related. Erythromycins and chloramphenicol target the large mitochondrial 
ribosome, while tetracyclines and glycylcyclines target the small mitochondrial ribosomes, because of conserved similarities with bacterial 
ribosomes. (B) Examples of FDA-approved antibiotics are shown. The structures of erythromycin (a) and tetracycline (b) are shown, along 
with pyrvinium pamoate (c). Here, we tested the hypothesis that these different classes of FDA-approved antibiotics could be re-purposed 
for the targeting of mitochondrial biogenesis and the eradication of cancer stem cells. 
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of cancer stem cells, allowing this approach to be more 
broadly applied perhaps to any cancer type (Figure 2). 
The Erythromycins: Azithromycin as an example
Azithromycin is a macrolide antibiotic that is 
currently used for the treatment of many types of bacterial 
infections. Azithromycin is a derivative of erythromycin, 
and is generally more potent and is more slowly eliminated 
than erythromycin, allowing infections to be treated 
relatively quickly, over 3-to-5 days. Overall, it shows 
broad-spectrum anti-bacterial activity. Mechanistically, 
azithromycin inhibits bacterial growth by preventing 
protein synthesis. Azithromycin directly binds to the 
50S subunit of the bacterial ribosome, and specifically 
inhibits the translation of mRNA species into protein. 
Importantly, the 50S bacterial ribosome is homologous the 
39S mitochondrial ribosome. In fact, many of the bacterial 
ribosomal subunits have directly-related mitochondrial 
homologues in eukaryotic cells. As such, erythromycin-
related antibiotics, e.g., azithromycin, behave as inhibitors 
of mitochondrial biogenesis. 
Thus, as a first step, we chose to evaluate the 
efficacy of azithromycin. For this purpose, azithromycin 
was tested for its ability to inhibit mammo-sphere 
formation using MCF7 and T47D cells, over a range of 
concentrations. Interestingly, in MCF7 cells, azithromycin 
inhibited mammo-sphere formation with an IC-50 of ~50 
µM; similar results were also obtained in T47D cells 
(Figure 3). 
As a consequence of these positive findings, we next 
tested the ability of azithromycin to inhibit tumor-sphere 
formation in a wide-variety of cell lines derived from 
many different tumor types, including ER(-) breast cancer, 
ovarian, lung, pancreatic, and prostate cancer, as well as 
melanoma (summarized in Table 1). For simplicity, we 
used a single concentration of 250 µM. Figure 4 (panels A 
and B) directly shows that azithromycin inhibited tumor-
sphere formation in these 8 additional well-established 
cell lines, representing 6 different cancer types. Thus, 
Figure 2: Treating cancer phenotypically as a single 
disease of increased “stemness”: Developing a 
mutation-independent approach to cancer therapy. 
One idea is that we could potentially treat cancer as a single 
disease, if we could identify a global phenotypic characteristic 
that is conserved across multiple cancer types. For this purpose, 
we focused on tumor-initiating cells (TICs), a.k.a., cancer stem 
cells (CSCs), as they share many common properties, such as 
anchorage-independent growth, i.e., tumor-sphere formation 
under low-attachment conditions. This global phenotypic 
property appears to be functionally dependent on increased 
mitochondrial biogenesis. 
Figure 3: Azithromycin dose-dependently inhibits 
tumor-sphere formation in MCF7 and T47D cells, 
two commonly used ER(+) breast cancer cell lines. 
Azithromycin was initially tested over the range of 50 µM to 
250 µM. Note that 250 µM was the most effective. (*)p <0.001.
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azithromycin was effective against tumor-sphere 
formation in all 10 cell lines tested. 
The Tetracyclines: Doxycycline provides proof-of-
concept
Tetracycline is a broad-spectrum antibiotic that 
is commonly used for the treatment many bacterial 
infections, and functions as an inhibitor of protein synthesis 
in bacteria. Today, it is mainly used for the treatment of 
acne. However, the term “tetracyclines” is also used to 
describe a class of related semi-synthetic derivatives, that 
all contain the same chemically-conserved four-member 
ring structure, that is characteristic of tetracycline. 
Tetracyclines show bacterio-static activity against nearly 
all aerobic and anaerobic bacteria, including both Gram-
positive and Gram-negative types. Tetracyclines inhibit 
protein synthesis by preventing the binding of activated 
aminoacyl-tRNAs to the A-site on the 30S subunit of 
bacterial ribosomes. As such, they reversibly inhibit the 
addition of new amino acids to the growing polypeptide 
chain, during protein synthesis. Importantly, the 30S 
bacterial ribosome is homologous the 28S mitochondrial 
Figure 4: Azithromycin inhibits tumor-sphere formation in eight other cell lines, derived from diverse cancer types. 
For simplicity, the efficacy of azithromycin was tested at a concentration of 250 µM. (*)p <0.001. (A) ER(-) breast [MDA-MB-231] and 
ovarian cancer cell lines [SKOV3, ES2, Tov21G] (B) Lung [A549], prostate [PC3], melanoma [A375], and pancreatic [MIA PaCa2].
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ribosome, accounting for the manageable side-effects of 
the tetracyclines. As a consequence, tetracycline-based 
antibiotics are inhibitors of mitochondrial biogenesis. 
Doxycycline is a tetracycline-derivative with markedly 
improved efficacy and stability, which was first FDA-
approved in the late 1960s, nearly 50 years ago now. 
Thus, we next evaluated the efficacy of the 
tetracycline-based antibiotic, doxycycline. More 
specifically, doxycycline was tested for its ability to inhibit 
mammo-sphere formation using MCF7 and T47D cells, 
over a large range of concentrations, from 1 µM to 250 
µM. Interestingly, in MCF7 cells, doxycycline inhibited 
mammo-sphere formation with an IC-50 between 2 and 10 
µM; virtually identical results were also obtained in T47D 
cells (Figure 5). 
We then tested the ability of doxycycline to inhibit 
tumor-sphere formation in a broad panel of cancer cell 
lines derived from many different tumor types (Table 1). 
For simplicity, we used a single concentration of 50 µM. 
Figure 6 (panels A and B) directly shows that doxycycline 
inhibited tumor-sphere formation in all of these well-
established cell lines. Thus, doxycycline was effective 
against tumor-sphere formation in all 10 cell lines tested, 
across 6 different cancer types. 
The Glycylcyclines: Tigecycline shows efficacy
The glycylcyclines are a relatively new antibiotic 
class that are highly-related to the tetracyclines. The 
glycylcyclines were designed to specifically overcome 
tetracycline resistance. They have essentially the same 
mechanism of action as the tetracyclines, as they prevent 
bacterial protein synthesis. Both tetracyclines and 
glycylcyclines bind to the 30S bacterial ribosomal subunit, 
thereby inhibiting the binding of a given aminoacyl-tRNA 
to the A-site of the ribosome. Importantly, it appears that 
glycylcyclines bind more tightly to the ribosome, than 
the tetracyclines. Currently, tigecycline is the only FDA-
approved glycylcycline. Similarly, the glycylcyclines are 
inhibitors of mitochondrial biogenesis.
Interestingly, quantitatively similar results 
were obtained with tigecycline, as compared with 
doxycycline, showing that it also has the capacity to 
inhibit tumor-sphere formation, across all 10 cell lines 
tested. Tigecycline was first tested for its ability to inhibit 
mammo-sphere formation using MCF7 and T47D cells, 
over a concentration range, from 10 µM to 50 µM. 
Interestingly, in both MCF7 and T47D cells, tigecycline 
inhibited mammo-sphere formation with an IC-50 between 
10 and 25 µM (Figure 7). For simplicity, we used a single 
concentration of 50 µM, in all eight other cell lines, which 
significantly inhibited tumor-sphere formation (Figures 8).
Anti-parasitc drugs: Pyrvinium pamoate
Pyrvinium is a cyanine dye, which is an FDA-
approved anti-helmintic drug, that has been used to treat 
pinworms, as well as strongyloidiasis in humans. It was 
first approved by the FDA in 1955 for the treatment 
of enterobiasis, and is known to act as an inhibitor of 
mitochondrial oxidative phosphorylation (OXPHOS), 
under both normoxia and hypoxic conditions. Several 
forms of pyrvinium have been prepared, with different 
anions. Here, we tested the efficacy of pyrvinium 
pamoate. We used this approach to further validate that 
mitochondrial function was indeed critical for the survival 
and propagation of cancer stem cells. 
For this purpose, pyrvinium pamoate was tested for 
its ability to inhibit mammo-sphere formation using MCF7 
and T47D cells, over a range of concentrations, from 1 nM 
to 500 nM. Interestingly, in both MCF7 and T47D cells, 
pyrvinium pamoate inhibited mammo-sphere formation 
with an IC-50 between ~10-to-50 nM (Figure 9). 
As such, we next tested the ability of pyrvinium 
pamoate to inhibit tumor-sphere formation in a wide-
variety of cell lines derived from many different tumor 
types (listed in Table 1); we used two concentrations of 
250 nM and 500 nM. Figure 10 (panels A and B) illustrates 
that pyrvinium pamoate inhibited tumor-sphere formation 
across the entire cell line panel; pyrvinium pamoate was 
Figure 5: Doxycycline dose-dependently inhibits 
tumor-sphere formation in MCF7 and T47D cells, 
two commonly used ER(+) breast cancer cell lines. 
Doxcycline was initially tested over the range of 1 µM to 250 
µM. Note that 50-to-100 µM was the most effective. (*)p <0.001.
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Figure 6: Doxycycline inhibits tumor-sphere formation in eight other cell lines, derived from diverse cancer types. For 
simplicity, the efficacy of doxycycline was tested at a concentration of 50 µM. (*)p <0.001. (A) ER(-) breast [MDA-MB-231] and ovarian 
cancer cell lines [SKOV3, ES2, Tov21G] (B) Lung [A549], prostate [PC3], melanoma [A375], and pancreatic [MIA PaCa2].
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effective against tumor-sphere formation in all 10 cell 
lines tested, in the nano-molar range. 
Efficacy of four classes of antibiotics against DCIS 
and Glioblastoma CSCs
To further assess the efficacy of these four classes 
of antibiotics, we also determined their effectiveness in 
inhibiting tumor-sphere formation using two other well-
established cell lines. One was a DCIS-based human cell 
line, namely MCF10.DCIS.com, which is often used to 
model pre-malignant mammary lesions in breast cancer 
patients. The other was derived from one of the most 
malignant and aggressive tumor types, glioblastoma (brain 
cancer; U-87 MG). 
Figure 11 (panels A and B) shows that all four 
classes of antibiotics significantly inhibited tumor-sphere 
formation in both DCIS.com and U-87 MG cells. Thus, 
our approach can also be used to target both pre-malignant 
lesions, such as DCIS, or even the most invasive and 
aggressive cancer types, such as glioblastoma. 
Importantly, azithromycin, doxycycline, and 
tigecycline are all known to cross the blood-brain barrier, 
making the treatment of brain cancer with these antibiotics 
feasible. 
Evaluating possible toxicity in “bulk” cancer cells 
and normal fibroblasts
To evaluate the possible toxicity of our approach on 
”bulk” cancer cells and normal fibroblasts, we next used i) 
MCF7 cell monolayers and ii) hTERT-immortalized skin 
fibroblasts, and assessed their viability using the MTS 
assay. For these experiments, we focused on two drugs, 
namely doxycycline and pyrvinium pamoate. 
For doxycycline, we used a concentration range 
from 50 µM to 500 µM. Note that there was little or no 
toxicity observed in MCF7 cell monolayers or hTERT-
BJ1 fibroblasts, over this entire range (Figure 12, panels A 
and B). Importantly, 50 µM doxycycline reduced MCF7 
mammosphere formation by >95% (Figure 5). Thus, 
there is no toxicity for MCF7 cell monolayers or normal 
fibroblasts at a concentration that nearly completely 
eliminates CSC expansion (and even at 10X times higher). 
For pyrvinium pamoate, we used a concentration 
range from 500 nM to 5 µM. Importantly, there was 
little or no toxicity observed in MCF7 cell monolayers 
or hTERT-BJ1 fibroblasts (Figure 13, panels A and B). 
Interestingly, 500 nM pyrvinium pamoate reduced MCF7 
mammosphere formation by >99% (Figure 9). As such, 
there is little or no toxicity for MCF7 cell monolayers or 
normal fibroblasts at a concentration that eliminates CSC 
expansion (and even at 10X times higher).
Importantly, we observed very limited toxicity, 
which is consistent with fact that these are well-tolerated 
antibiotics that are already FDA-approved for patient 
therapy, but are normally used in the context of infectious 
disease. 
Chloramphenicol
Chloramphenicol is a bacterio-static antibiotic used 
for the treatment of a number of bacterial infections, 
which first became available in the late 1940s. It is a 
typical broad-spectrum antibiotic. Like the eyrthromycins 
and the tetracyclines, it functions as an inhibitor of protein 
synthesis, by binding to the 50S bacterial ribosomal 
subunit, thereby inhibiting peptide bond formation. 
More specifically, it inhibits peptidyl-transferase activity, 
preventing protein chain elongation. Similarly, in 
mammalian cells, chloramphenicol behaves an inhibitor 
of mitochondrial biogenesis.
Thus, we chose to evaluate the efficacy of 
chloramphenicol and determined its ability to inhibit 
mammo-sphere formation using MCF7 cells, over a range 
of concentrations from 10 µM to 1 mM. Interestingly, in 
MCF7 cells, chloramphenicol inhibited mammo-sphere 
formation with an IC-50 of ~200 µM (Figure 14). As 
such, we have now shown that four independent antibiotic 
inhibitors of mitochondrial biogenesis (azithromycin, 
doxycycline, tigecycline, and chloramphenicol) all 
Figure 7: Tigecycline dose-dependently inhibits 
tumor-sphere formation in MCF7 and T47D cells, 
two commonly used ER(+) breast cancer cell lines. 
Tigecycline was initially tested over the range of 10 µM to 50 
µM. Note that 50 µM was the most effective. (*)p <0.001.
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Figure 8: Tigecycline inhibits tumor-sphere formation in eight other cell lines, derived from diverse cancer types. For 
simplicity, the efficacy of tigecycline was tested at a concentration of 50 µM. (*)p <0.001. (A) ER(-) breast [MDA-MB-231] and ovarian 
cancer cell lines [SKOV3, ES2, Tov21G] (B) Lung [A549], prostate [PC3], melanoma [A375], and pancreatic [MIA PaCa2].
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effectively inhibit mammo-sphere formation. However, 
chloramphenicol was the least potent of the mitochondrial 
inhibitors that we tested. 
DISCUSSION
Here, we showed that 4-to-5 different classes of 
FDA-approved antibiotics can be used to selectively target 
CSCs, across multiple tumor types. Mechanistically, these 
antibiotics converge on three main mitochondrial targets, 
as summarized in Figure 15. Thus, molecular disruption 
of mitochondrial biogenesis or OXPHOS would be a 
novel therapeutic strategy for the eradication of CSCs. 
As a result, our findings have broad implications for 
the initiation of new clinical trials, for the re-purposing 
of antibiotics for the treatment of various cancer types, 
including “pre-malignant” and advanced metastatic 
disease. 
This new therapeutic strategy takes advantage of 
the manageable side-effects of these antibiotics, which 
affect eukaryotic mitochondria, although these compounds 
are currently used for the broad-spectrum treatment of 
bacterial and parasitic infectious diseases. 
In this regard, doxycycline is relatively attractive 
as a new anti-cancer agent, as it has a long half-life 
systemically and has been used successfully for the long-
term treatment of patients with urinary tract infections 
(UTI), prostatitis or acne, for extended periods of time, 
of up to 4-to-6 months or more (200 mg per day). 
Doxycycline also encourages the growth of normal stem 
cells, has anti-inflammatory properties, and even increases 
lifespan, in certain experimental contexts [12-14]. Thus, 
the toxic side effects of anti-cancer therapy would be 
minimized. 
Doxycycline has also been used in human tumor 
xenografts and other animal models to significantly reduce 
tumor burden and even metastatic cancer cell growth [15-
20]. For example, in pancreatic tumor xenografts (with 
PANC-1 cells), doxycycline treatment reduced tumor 
growth by ~80% [20]. In a xenograft model of breast 
cancer bone metastasis (with MDA-MB-231 cells), 
doxycycline treatment reduced bone and bone-associated 
soft-tissue tumor mass by >60% and ~80%, respectively 
[19]. However, its anti-cancer activity was attributed to 
the inhibition of matrix-metalloproteinases (MMPs), 
rather than the targeting of mitochondrial biogenesis, and 
doxycycline has not been previously implicated in the 
selective eradication of cancer stem cells [15-20]. 
Our results are consistent with the previous finding 
that metformin, a widely used anti-diabetic drug, which 
functions as a mitochondrial inhibitor, can also be used to 
selectively target CSCs [21, 22]. Metformin functionally 
inhibits OXPHOS by targeting complex I of the electron 
transport chain and can even induce lactic acidosis, 
as a lethal side effect [21, 22]. As a result, the use of 
antibiotics, such as doxycycline, may provide a safer and 
far more effective alternative to anti-cancer therapy with 
metformin. 
Our global phenotypic approach to target cancer as 
a single disease of stemness, may also help to avoid drug 
resistance. We speculate that genetic changes (oncogenic 
mutations, amplifications/deletions, and tumor suppressor 
loss) all converge on “stemness” in tumor-initiating 
CSCs (Figure 16), driving tumor recurrence, metastasis 
and drug resistance. Thus, it would be advantageous to 
phenotypically target “stemness” directly, instead of 
targeting individual genetic changes, in different cancer 
types. This would allow the treatment of cancer in a 
mutation-independent fashion. 
Finally, recent clinical trials with doxycycline 
and azithromycin (intended to treat cancer-associated 
infections, but not cancer cells) both show positive 
therapeutic effects in cancer patients, although their 
selective effects on eradicating cancer stem cells were 
not yet known or appreciated [23-26]. These trials were 
performed on advanced or treatment-resistant patients 
with B-cell lymphoma (doxycycline) or lung cancer 
(azithromycin), respectively [23-26]. For example, in 
lung cancers, azithromycin significantly increased 1-year 
patient survival from 45% to 75%, an ~1.7-fold increase 
[26]. Interestingly, it was noted that even lymphoma 
patients that were “bacteria-free” benefited from only 
a 3-week course of doxycycline therapy, and showed 
complete remission of the disease [27]. These results 
Figure 9: Pyrvinium pamoate dose-dependently 
inhibits tumor-sphere formation in MCF7 and T47D 
cells, two commonly used ER(+) breast cancer cell 
lines. Pyrvinium pamoate was initially tested over the range of 
1 nM to 500 nM. Note that 250 nM and 500 nM were the most 
effective. (*)p <0.001.
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Figure 10: Pyrvinium pamoate inhibits tumor-sphere formation in eight other cell lines, derived from diverse cancer 
types. For simplicity, the efficacy of pyrvinium pamoate was tested at a concentration of 250 nM and 500 nM. (*)p <0.001. (A) ER(-) 
breast [MDA-MB-231] and ovarian cancer cell lines [SKOV3, ES2, Tov21G] (B) Lung [A549], prostate [PC3], melanoma [A375], and 
pancreatic [MIA PaCa2].
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Figure 11: Four FDA-approved antibiotic classes also inhibit tumor-sphere formation in DCIS and glioblastoma cell 
lines. Antibiotics were tested at the following concentrations: azithromycin (250 µM), doxycycline (50 µM), tigecycline (50 µM), and 
pyrvinium pamoate (250 and 500 nM). Note that all four antibiotics classes inhibit tumor-sphere formation, in both DCIS and glioblastoma 
cell lines. (A) DCIS.com; (B) U-87 MG. (*)p <0.001.
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Figure 12: Doxycycline does not affect the viability of 
“bulk” cancer cells or normal fibroblasts. (A) MCF7 
cell monolayers; (B) hTERT-BJ1 skin fibroblasts. Viability 
was quantitatively measured using the MTS assay. Doxcycline 
was tested over the range of 50 µM to 500 µM, with little or no 
effects on cell viability. 
Figure 13: Pyrvinium pamoate does not affect the 
viability of “bulk” cancer cells or normal fibroblasts. 
(A) MCF7 cell monolayers; (B) hTERT-BJ1 skin fibroblasts. 
Viability was quantitatively measured using the MTS assay. 
Pyrvinium pamoate was tested over the range of 500 nM to 5 
µM, with little or no effects on cell viability. 
Figure 14: Chloramphenicol dose-dependently inhibits tumor-sphere formation in MCF7 cells. We determined the 
ability of chloramphenicol to inhibit mammo-sphere formation using MCF7 cells, over a range of concentrations from 10 µM to 1 mM. 
Interestingly, in MCF7 cells, chloramphenicol inhibited mammo-sphere formation with an IC-50 of ~200 µM. (*)p <0.002.
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suggest that the antibiotic’s therapeutic effects were 
actually infection-independent. 
Thus, future clinical trials for testing the efficacy 
of mitochondrially-targetd antibiotics in multiple cancer 
types are now clearly clinically warranted. In this regard, 
a clinical trial with doxycycline in patients with advanced 
breast cancer and bone metastasis is ongoing: https://
clinicaltrials.gov/ct2/show/NCT01847976. Secondly, 
a trial of doxycycline in relapsed patients with non-
hodgkin’s lymphoma has also been initiated: https://
clinicaltrials.gov/ct2/show/NCT02086591. Interestingly, 
the A375 human melanoma cell line harbors the 
B-RAF(V600E) mutation and we showed that CSCs 
derived from this cell line are highly-sensitive to all four of 
the antibiotics that we tested (azithromcyin, doxycycline, 
tigecycline, and pyrvinium pamoate). As such, additional 
cellular studies, and new clinical trails in melanoma 
patients with B-RAF mutations, may be indicated, to 
explore the use of antibiotics. 
Figure 15: Summary of drug discovery. The five-classes of antibiotics that we tested are summarized here, along with their three 
corresponding molecular targets, which all converge on mitochondrial biogenesis or OXPHOS. 
Figure 16: A mutation-independent approach to cancer therapy. We speculate that genetic changes (oncogenic mutations, 
amplifications/deletions, and tumor suppressor loss) all converge on “stemness” in tumor-initiating cells, driving tumor recurrence, 
metastasis and drug resistance. Thus, it would be advantageous to phenotypically target “stemness” directly, instead of targeting individual 
genetic changes, in different cancer types. This would allow the treatment of cancer as a single disease of stemness, in a mutation-
independent fashion.
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MATERIALS AND METHODS
Materials
Cancer cell lines were purchased from the ATCC or 
other commercially available sources. Antibiotics were all 
obtained commercially from Sigma-Aldrich. Gibco-brand 
cell culture media (DMEM/F12) was purchased from Life 
Technologies. 
Tumor-sphere Culture
A single cell suspension was prepared using 
enzymatic (1x Trypsin-EDTA, Sigma Aldrich, #T3924), 
and manual disaggregation (25 gauge needle) to create a 
single cell suspension. Cells were plated at a density of 
500 cells/cm2 in mammosphere medium (DMEM-F12/
B27/20ng/ml EGF/PenStrep) in non-adherent conditions, 
in culture dishes coated with (2-hydroxyethylmethacrylate) 
(poly-HEMA, Sigma, #P3932) [28]. Cells were grown for 
5 days and maintained in a humidified incubator at 37°C 
at an atmospheric pressure in 5% (v/v) carbon dioxide/air. 
After 5 days for culture, spheres >50 µm were counted 
using an eye piece graticule, and the percentage of cells 
plated which formed spheres was calculated and is referred 
to as percentage tumor-sphere formation (TSF), and was 
normalized to one (1 = 100 % TSF) [28]. All experiments 
were performed in triplicate, three times independently, 
such that each data point represents the average of 9 
replicates. 
For tumor-sphere assays, all cell line derived 
spheroids (MCF7, T47D, MDA-MB-231, DCIS.com, 
SKOV3, Tov21G, ES2, and A549) were counted at 5 days 
after plating, with the exception of PC3, A375, and MIA 
PaCa2 cells, which were counted at 3 days post-seeding. 
Finally, U-87 MG spheroids were counted at 7 days. All 
data shown are the mean +/- the standard error of the mean 
(SEM).
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